Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive profiling of 1015 patients' exomes reveals genomic-clinical associations in colorectal cancer.
Zhao Q, Wang F, Chen YX, Chen S, Yao YC, Zeng ZL, Jiang TJ, Wang YN, Wu CY, Jing Y, Huang YS, Zhang J, Wang ZX, He MM, Pu HY, Mai ZJ, Wu QN, Long R, Zhang X, Huang T, Xu M, Qiu MZ, Luo HY, Li YH, Zhang DS, Jia WH, Chen G, Ding PR, Li LR, Lu ZH, Pan ZZ, Xu RH. Zhao Q, et al. Among authors: zhang ds, zhang j, zhang x. Nat Commun. 2022 Apr 29;13(1):2342. doi: 10.1038/s41467-022-30062-8. Nat Commun. 2022. PMID: 35487942 Free PMC article.
Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial.
Ruan DY, Liu FR, Wei XL, Luo SX, Zhuang ZX, Wang ZN, Liu FN, Zhang YQ, Yang JW, Chen ZD, Wang YS, Wang JY, Liang XH, Wu XJ, Zheng YL, Liu J, Shi X, Kumar R, Liu W, Chen B, Zhang DS, Xu RH. Ruan DY, et al. Among authors: zhang ds. Lancet Oncol. 2025 Jan 6:S1470-2045(24)00636-3. doi: 10.1016/S1470-2045(24)00636-3. Online ahead of print. Lancet Oncol. 2025. PMID: 39788133
Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab in patients with advanced solid tumors: results from two phase I trials.
Liu FR, Wei XL, Feng WN, Zhao HY, Zhang Y, Wang ZQ, Zhang DS, Wang FH, Yang S, Pan W, Tian X, Men L, Wang H, Liang E, Wang C, Yang D, Zhai Y, Qiu MZ, Xu RH. Liu FR, et al. Among authors: zhang ds. ESMO Open. 2024 Aug;9(8):103651. doi: 10.1016/j.esmoop.2024.103651. Epub 2024 Jul 25. ESMO Open. 2024. PMID: 39059062 Free PMC article. Clinical Trial.
409 results